



---

## Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

---

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-03261-7>,

published online 13 September 2024.







---

<https://doi.org/10.1038/s41591-024-03349-0>

---

Published online: 9 December 2024

---

Nadia Harbeck , Eva Ciruelos , Guy Jerusalem , Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J. Higgins, Roisin M. Connolly , Sally Baron-Hay , María Gión, Valentina Guarneri, Giampaolo Bianchini , Hans Wildiers , Santiago Escrivá-de-Romaní, Manoj Prahlanan, Helen Bridge, Nataliya Kuptsova-Clarkson, Nana Scotto, Sunil Verma, Nancy U. Lin  & the DESTINY-Breast12 study group\*

---

In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies *n* (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows. In Table 1 and in the Results: Patients section, “intracranial therapy” has been amended to “CNS radiotherapy,” while the text “the type of intracranial radiotherapy was not always recorded by investigators, and only WBRT and SRS intracranial radiotherapy were reported” has been removed. All changes appear in the HTML and PDF versions of the article.

---

\*A list of authors and their affiliations appears online.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024